Richard Pascoe

San Diego, California, United States
Mr. Pascoe joined Histogen following the merger of Apricus Biosciences Inc. and Seelos Therapeutics. Mr. Pascoe was the CEO of Apricus from March 2013 until 2019. Prior to Apricus, Mr. Pascoe was with Somaxon Pharmaceuticals, Inc. where he served as the CEO.
Prior to joining Somaxon in 2008, Mr. Pascoe served as COO at ARIAD Pharmaceuticals. Prior to ARIAD, Mr. Pascoe held a series of senior management roles at King Pharmaceuticals. Prior to King, Mr. Pascoe held commercial roles at Medco Research, COR Therapeutics., and B. Braun Interventional.
Mr. Pascoe is a member of the board of directors of KemPharm. He also serves as a member of the board of directors of Seelos Therapeutics. He is also a member of the board of directors of Biocom, and the Johnny Mac Soldiers Fund.
Mr. Pascoe served as a Commissioned Officer with the U.S. Army’s earning the Bronze Star Medal. He is a 1986 graduate of West Point where he received a B.S. in Leadership.
Speaking In
[Available On-Demand]
Histogen is a regenerative medicine company with a unique biological platform that replaces and…